Geode Capital Management
NMRA icon

Geode Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Geode Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.43M Buy
2,607,289
+1,520,424
+140% +$2.89M ﹤0.01% 2977
2026
Q1 		$2.12M Buy
1,086,865
+83,119
+8% +$215K ﹤0.01% 3094
2025
Q4 		$1.8M Buy
1,003,746
+34,818
+4% +$76.2K ﹤0.01% 3205
2025
Q3 		$1.76M Buy
968,928
+52,113
+6% +$84.2K ﹤0.01% 3219
2025
Q2 		$673K Sell
916,815
-1,059,487
-54% -$803K ﹤0.01% 3463
2025
Q1 		$1.98M Buy
1,976,302
+6,022
+0.3% +$10.3K ﹤0.01% 3033
2024
Q4 		$20.9M Sell
1,970,280
-9,567
-0.5% -$115K ﹤0.01% 1947
2024
Q3 		$26.2M Buy
1,979,847
+694,385
+54% +$8.1M ﹤0.01% 1835
2024
Q2 		$12.6M Buy
1,285,462
+833,081
+184% +$8.62M ﹤0.01% 2182
2024
Q1 		$6.22M Buy
452,381
+15,504
+4% +$251K ﹤0.01% 2576
2023
Q4 		$7.45M Buy
436,877
+314,691
+258% +$3.86M ﹤0.01% 2492
2023
Q3 		$1.72M Buy
+122,186
New +$1.53M ﹤0.01% 3120

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management's NMRA Position: Q2 2026 in Review

Geode Capital Management increased its Neumora Therapeutics (NMRA) stake by 140% in Q2 2026, buying an estimated $2.89M and bringing the position to 2,607,289 shares worth $4.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2977.

Geode Capital Management first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $26.2M in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Geode Capital Management held 2,607,289 shares of Neumora Therapeutics worth $4.43M as of Q2 2026.
  • Geode Capital Management bought 1,520,424 Neumora Therapeutics shares in Q2 2026, an estimated $2.89M.
  • Neumora Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2977 holding.
  • Geode Capital Management first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Geode Capital Management's Neumora Therapeutics position peaked at $26.2M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.